Paragon Capital Management (Utah)’s Regeneron Pharmaceuticals REGN Stock Holding History

Paragon Capital Management (Utah)’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-2,159	Closed	-$1.21M	–	85
2025 Q3	$1.21M	Sell	2,159 -47	-2%	-$26.6K	0.91%	42
2025 Q2	$1.16M	Sell	2,206 -4	-0.2%	-$2.23K	0.88%	45
2025 Q1	$1.4M	Buy	2,210 +446	+25%	+$307K	1.13%	31
2024 Q4	$1.26M	Buy	+1,764	New	+$1.48M	0.98%	42
2022 Q1	–	Sell	-1,148	Closed	-$725K	–	78
2021 Q4	$725K	Buy	+1,148	New	+$706K	0.62%	51

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Paragon Capital Management (Utah)'s REGN Position: Q4 2025 in Review

Paragon Capital Management (Utah) sold out of Regeneron Pharmaceuticals (REGN) in Q4 2025, closing a stake of 2,159 shares — an estimated $1.21M sold.

Paragon Capital Management (Utah) first reported a position in REGN in Q4 2021 and held it in 5 quarters. The position peaked at $1.4M in Q1 2025. 1,387 funds tracked by Wall St. Rank hold REGN as of Q4 2025.

Paragon Capital Management (Utah) reported no remaining Regeneron Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Paragon Capital Management (Utah) sold 2,159 Regeneron Pharmaceuticals shares in Q4 2025, an estimated $1.21M.
Paragon Capital Management (Utah) first reported a position in Regeneron Pharmaceuticals in Q4 2021 and held it in 5 quarters.
Paragon Capital Management (Utah)'s Regeneron Pharmaceuticals position peaked at $1.4M in Q1 2025.
1,387 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2025.

Based on Paragon Capital Management (Utah)'s 13F filing for Q4 2025, filed 23 Jan 2026.